Strategic Partnerships Tizona has a history of high profile collaborations with AbbVie and Gilead, including equity investments and exclusive options, signaling openness to licensing and co-development deals as a route to access its pipeline.

First-in-class Focus The company pursues novel immunotherapies that modulate immune suppression in tumors and autoimmune diseases, including work on HLA-G, presenting licensing or collaboration opportunities for pharma seeking unique immuno-oncology targets.

Lean Clinical Stage As a small clinical-stage biotech, Tizona relies on external CROs, CMOs, and regulatory partners; this creates sales opportunities for outsourced trial management, development services, and manufacturing partnerships to accelerate programs.

Investor Backing Backed by major investors with strategic stakes in the company, there is clear appetite for external partnerships and potential co-development funding as programs advance.

Bay Area Advantage Based in South San Francisco, the company sits in a dense biotech ecosystem that offers easy access to CROs, contract manufacturers, and academic collaborators, enabling locally sourced partnerships and faster trial execution.